Starmer Faces Backlash Over NHS Drug Price Deal with Trump

The three-year agreement, announced by the Office of the United States Trade Representative, is expected to cost British taxpayers approximately £3 billion. Critics argue the move amounts to a capitulation to the pharmaceutical industry, prioritizing corporate profits over patient care. Liberal Democrat MP Helen Morgan described the arrangement as a "Trump shakedown," noting that US Health and Human Services Secretary Robert F. Kennedy Jr. openly celebrated the deal as a victory for American interests.

Health economics researcher Andrew Hill warned that the increased expenditure on drugs will inevitably divert resources away from essential services like ambulances and nursing staff. Public opposition remains high, with recent survey data indicating 64% of the British public rejects the idea of the NHS paying higher prices for medication. Advocacy groups, including Just Treatment and Global Justice Now, have called on Parliament to force a vote on the agreement, labeling it a betrayal of patients who already face significant gaps in care. When asked during a White House briefing whether the deal would actually lower costs for American consumers, Press Secretary Karoline Leavitt could not provide an immediate response.